Moleculin Biotech (MBRX)
Developing Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia.
Something off on this page? Send us feedback.
Develops Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia, alongside WP1066, WP1220, and WP1122 oncology programs. A virtual development model outsources manufacturing and has no approved products, product-sales revenue, or sales organization.
Develops Annamycin (naxtarubicin), a liposomal anthracycline, with cytarabine as AnnAraC for second-line relapsed or refractory acute myeloid leukemia. The pivotal MIRACLE trial runs across the United States and Europe. Other programs include WP1066 for brain tumors, WP1220 for cutaneous T-cell lymphoma, and WP1122 for metabolism/glycosylation inhibition.
Operates as a small, primarily virtual clinical development organization, using service providers and contractors worldwide while outsourcing all manufacturing. No approved products, product-sales revenue, or sales organization exist; any commercialization would require building those capabilities or using third parties.
Depends on clinical results, regulatory approval, additional financing, and MD Anderson licenses that carry fees, milestones, and potential royalties. AnnAraC is the only internally led pivotal program; other development efforts are completed, inactive, planned, partner-oriented, or investigator-led.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.3M · Total debt $292.0K · Total assets $21.1M · Shareholders' equity $11.6M
- Revenue
- $0
- Operating income
- −$7.6M
- Net income
- −$7.6M
No dividends on record.
| Institutions20 holders · as of Mar 31, 2026 | 0.78% | 152.1K shares | |
| Insiders3 holders · as of Aug 25, 2026 | 18.14% | 3.53M shares | |
| Strategic holders1 holder · as of Aug 10, 2026 | 9.57% | 1.86M shares | |
| Otherremainder | 71.51% | 13.93M shares |
19.48M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (19.48M in the company's Sep 3, 2026 report, 5.34M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Walter V. Klemp1Insiderdirector, officer: CEO and President | 10.63% | 2.07M | 13Dfiled Aug 25, 2026 ↗ |
CVI Investments, Inc.Strategic | 9.57% | 1.86M | 13Gfiled Aug 10, 2026 ↗ |
Jonathan P. Foster2Insiderofficer: Chief Financial Officer | 6.61% | 1.29M | 13Dfiled Aug 25, 2026 ↗ |
Donald H. PickerInsiderofficer: Chief Science Officer | 0.89% | 174,086 | Form 4filed Aug 5, 2026 ↗ |
Sabby Management, LLCInstitution | 0.39% | 75,021 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Walter V. Klemp's transaction reports restate only vehicles that traded; the 2026 ownership statement (2.07M) is used instead.
- Jonathan P. Foster's transaction reports restate only vehicles that traded; the 2026 ownership statement (1.29M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 3, 2026 | Donald H. Picker | officer: Chief Science Officer | +693,332 | $0.7500 |
| Aug 3, 2026 | Walter V. Klemp | director, officer: CEO and President | +533,333 | $0.7500 |
| Aug 3, 2026 | Jonathan P. Foster | officer: Chief Financial Officer | +1,173,332 | $0.7500 |
- Jazz Pharmaceuticals
Liposomal daunorubicin-cytarabine alternative in AML induction.
- Bristol-Myers Squibb
IDH2-targeted option for mutation-defined R/R AML.
- Kura
NPM1-targeted option for relapsed or refractory AML.
- Syndax Pharmaceuticals
Menin-inhibitor option in NPM1- and KMT2A-defined R/R AML.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Moleculin Biotech | $0.6912 | −0.87% | $3.7M | — | — | — | — |
| Jazz Pharmaceuticals | $246.83 | +0.55% | $15.43B | 16.8 | 9.7 | 3.4 | +15.6% |
| Bristol-Myers Squibb | $67.64 | −0.02% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Kura | $13.58 | +3.62% | $1.16B | — | — | 15.1 | +36.5% |
| Syndax Pharmaceuticals | $20.79 | +3.43% | $1.84B | — | — | 7.3 | +91.8% |
| Median | 15.8 | 10.2 | 5.3 | +26.0% |